Literature DB >> 22552573

Pharmacokinetics of subconjunctival injection of moxifloxacin in humans.

Kazuki Matsuura.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552573     DOI: 10.1007/s00417-012-2036-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Severe anaphylactic reaction after intracameral antibiotic administration during cataract surgery.

Authors:  José R Villada; Ubaldo Vicente; Jaime Javaloy; Jorge L Alió
Journal:  J Cataract Refract Surg       Date:  2005-03       Impact factor: 3.351

2.  A survey of measures used for the prevention of postoperative endophthalmitis after cataract surgery in the United Kingdom.

Authors:  P Gordon-Bennett; A Karas; D Flanagan; C Stephenson; M Hingorani
Journal:  Eye (Lond)       Date:  2006-12-15       Impact factor: 3.775

3.  Association between nonadministration of subconjunctival cefuroxime and postoperative endophthalmitis.

Authors:  O J Lehmann; C J Roberts; K Ikram; M J Campbell; J I McGill
Journal:  J Cataract Refract Surg       Date:  1997 Jul-Aug       Impact factor: 3.351

4.  Randomised single blind trial to compare the toxicity of subconjunctival gentamicin and cefuroxime in cataract surgery.

Authors:  C D Jenkins; P J McDonnell; D J Spalton
Journal:  Br J Ophthalmol       Date:  1990-12       Impact factor: 4.638

5.  Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery.

Authors:  Marie-Noëlle Delyfer; Marie-Bénédicte Rougier; Sandy Leoni; Qiuhua Zhang; Francis Dalbon; Joseph Colin; Jean-François Korobelnik
Journal:  J Cataract Refract Surg       Date:  2011-02       Impact factor: 3.351

6.  Comparative intraocular penetration of topical and injected cefuroxime.

Authors:  C D Jenkins; S J Tuft; G Sheraidah; D A McHugh; R J Buckley
Journal:  Br J Ophthalmol       Date:  1996-08       Impact factor: 4.638

7.  Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.

Authors:  Seenu M Hariprasad; Kevin J Blinder; Gaurav K Shah; Rajendra S Apte; Brett Rosenblatt; Nancy M Holekamp; Matthew A Thomas; William F Mieler; Jingduan Chi; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2005-01

8.  Endophthalmitis after cataract surgery: risk factors relating to technique and events of the operation and patient history: a retrospective case-control study.

Authors:  P G Montan; G Koranyi; H E Setterquist; A Stridh; B T Philipson; K Wiklund
Journal:  Ophthalmology       Date:  1998-12       Impact factor: 12.079

9.  Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey.

Authors:  David F Chang; Rosa Braga-Mele; Nick Mamalis; Samuel Masket; Kevin M Miller; Louis D Nichamin; Richard B Packard; Mark Packer
Journal:  J Cataract Refract Surg       Date:  2007-10       Impact factor: 3.351

10.  Ocular penetration of subconjunctivally injected gentamicin, sisomicin and cephaloridine.

Authors:  M R Jain; M Goyal; V Jain
Journal:  Jpn J Ophthalmol       Date:  1988       Impact factor: 2.447

  10 in total
  3 in total

1.  Deep subconjunctival injection of gentamicin for the treatment of bacterial conjunctivitis in macaques (Macaca mulatta and Macaca fascicularis).

Authors:  Sylvia I Gografe; Barbara C Hansen; Kenneth D Hansen
Journal:  Lab Anim (NY)       Date:  2015-03       Impact factor: 12.625

2.  Injection volume and intracameral moxifloxacin dose.

Authors:  Neal H Shorstein; Susanne Gardner
Journal:  J Cataract Refract Surg       Date:  2019-08-20       Impact factor: 3.351

3.  Survey of Japanese ophthalmic surgeons regarding perioperative disinfection and antibiotic prophylaxis in cataract surgery.

Authors:  Kazuki Matsuura; Takafumi Mori; Takeshi Miyamoto; Chikako Suto; Yusuke Saeki; Shigeto Tanaka; Hajime Kawamura; Shinji Ohkubo; Masaki Tanito; Yoshitsugu Inoue
Journal:  Clin Ophthalmol       Date:  2014-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.